🇺🇸 UTHR — United Therapeutics Corporation
Salud CompraPrecio actual
562,02 USD
Máx. histórico
608,49
2 días
Split 2:1 del 23/09/2009
Caída desde máximo
-7,64%
Rango 52 semanas
444,04 – 614,23
Variación hoy
-0,65%
Cierre anterior
565,72
Rango de hoy
559,41 – 569,45
Volumen hoy
454.934
Peor caída histórica
-93,18%
12/07/2000 → 10/12/2001
Recuperado en 3311 días
Volatilidad anualizada ⓘ
46,96%
- Nombre completo
- United Therapeutics Corporation
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- Empleados
- 1.400
- PER ⓘ
- 21,22 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 670,93 USD (puede no estar actualizado)
- Primera cotización
- 17/06/1999
- Precio actualizado
- hace 3 horas
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Fecha | Ratio |
|---|---|
| 23/09/2009 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/04/2012 | 41,01 | 41,47 | 40,34 | 40,42 | -1,77% | 2,76% | 1.290.500 |
| 17/04/2012 | 41,43 | 41,79 | 41,12 | 41,15 | -0,46% | 1,62% | 748.100 |
| 16/04/2012 | 41,68 | 42,08 | 41,00 | 41,34 | -0,70% | 2,59% | 630.100 |
| 13/04/2012 | 42,12 | 42,51 | 41,60 | 41,63 | -1,77% | 2,16% | 546.700 |
| 12/04/2012 | 43,09 | 43,30 | 41,75 | 42,38 | -3,09% | 3,60% | 1.855.300 |
| 11/04/2012 | 44,01 | 44,45 | 43,58 | 43,73 | +0,09% | 1,98% | 467.500 |
| 10/04/2012 | 44,54 | 44,61 | 43,52 | 43,69 | -1,80% | 2,45% | 616.000 |
| 09/04/2012 | 44,28 | 44,72 | 44,01 | 44,49 | -0,47% | 1,60% | 652.500 |
| 05/04/2012 | 45,00 | 45,36 | 44,64 | 44,70 | -1,17% | 1,60% | 451.600 |
| 04/04/2012 | 46,65 | 46,82 | 45,06 | 45,23 | -3,97% | 3,77% | 1.130.200 |
| 03/04/2012 | 47,50 | 47,56 | 46,75 | 47,10 | -0,90% | 1,71% | 563.900 |
| 02/04/2012 | 46,94 | 47,58 | 46,37 | 47,53 | +0,85% | 2,58% | 560.200 |
| 30/03/2012 | 47,69 | 47,69 | 46,95 | 47,13 | -0,65% | 1,55% | 649.900 |
| 29/03/2012 | 47,84 | 47,84 | 47,00 | 47,44 | -1,43% | 1,76% | 677.400 |
| 28/03/2012 | 48,76 | 48,92 | 47,63 | 48,13 | -1,41% | 2,65% | 571.400 |
| 27/03/2012 | 48,73 | 49,13 | 48,39 | 48,82 | +0,39% | 1,52% | 512.800 |
| 26/03/2012 | 48,05 | 48,70 | 47,87 | 48,63 | +1,99% | 1,73% | 447.700 |
| 23/03/2012 | 47,88 | 48,23 | 47,60 | 47,68 | -0,29% | 1,32% | 534.500 |
| 22/03/2012 | 47,96 | 48,27 | 47,42 | 47,82 | -0,85% | 1,77% | 449.200 |
| 21/03/2012 | 48,10 | 48,63 | 47,78 | 48,23 | +0,82% | 1,77% | 386.200 |
| 20/03/2012 | 48,18 | 48,29 | 47,53 | 47,84 | -1,28% | 1,58% | 348.700 |
| 19/03/2012 | 47,96 | 48,81 | 47,86 | 48,46 | +1,23% | 1,98% | 382.700 |
| 16/03/2012 | 47,39 | 48,23 | 47,39 | 47,87 | +0,78% | 1,77% | 853.300 |
| 15/03/2012 | 46,65 | 47,67 | 46,40 | 47,50 | +2,04% | 2,72% | 583.300 |
| 14/03/2012 | 47,12 | 47,46 | 46,49 | 46,55 | -1,08% | 2,06% | 693.900 |
| 13/03/2012 | 46,27 | 47,07 | 46,00 | 47,06 | +2,10% | 2,31% | 600.400 |
| 12/03/2012 | 46,87 | 47,18 | 45,95 | 46,09 | -1,62% | 2,62% | 432.300 |
| 09/03/2012 | 46,91 | 47,23 | 46,59 | 46,85 | +0,02% | 1,36% | 527.800 |
| 08/03/2012 | 45,76 | 46,94 | 45,70 | 46,84 | +2,85% | 2,71% | 756.400 |
| 07/03/2012 | 45,69 | 45,76 | 45,01 | 45,54 | +0,00% | 1,64% | 804.500 |